Move Beyond Transient Transfection
Transient transfection has enabled early AAV development, but it introduces inherent limitations at scale—high cost of goods, supply chain dependency on GMP plasmids, process variability, and increasing operational complexity.
Xcite® AAV Producer Cell Line (PCL) Technology
Xcite® AAV Producer Cell Line (PCL) Technology represents a fundamental shift toward a biologics-style manufacturing model, enabling consistent, scalable AAV production without the need for large-scale plasmids, transfection reagents, or helper virus.
Productivity That Bends the Cost Curve
With Xcite® AAV PCL technology, customers can achieve:
- Consistent, best-in-class productivity
> 1 × 1012 viral genomes/mL titers at harvest demonstrated across multiple GFP and non-GFP clonal cell lines for research and customer projects -
High-quality vector output
Robust genome packaging and high genome integrity across evaluated constructs -
Comparable or higher infectivity
Demonstrated relative to transient transfection-derived materials -
Exceptional clonal stability
Stable productivity, genome integrity, and infectivity maintained over >30 passages -
Simplified workflows
No GMP plasmids. No large-scale transfection steps. Reduced process variability.
De-Risk Development with Speed and Insight
Xcite® AAV PCL technology helps de-risk AAV manufacturing by reducing process complexity and accelerating decision-making.
- Generate proof-of-concept material rapidly from stable pools
- Progress from DNA sequence to material in as little as ~3 months
- Identify top-performing clonal cell lines within ~6 months
- Provide materials of high purity and yield by downstream purification process
This approach supports earlier insight into manufacturability, quality attributes and productivity—before committing to late-stage manufacturing pathways.
Flexible Platform Deployment with Xcite® AAV PCL Technology
The Xcite® AAV technologies described can be accessed through research licenses, enabling therapeutic developers to evaluate and implement the platform within their own laboratories with appropriate Lonza expert guidance, or via Lonza’s development services.
Download the brochure for more information
